WeightWatchers reported quarterly results in line with Wall Street’s consensus for revenue, but continued to face a challenging top line environment as overall sales declined year on year. Management pointed to the rapid growth in its Core+ and Med+ tiers, as well as a deliberate shift in marketing allocation, as key drivers supporting gross margin expansion and improved operating profitability. CEO Stephen Bye called out a “remarkable history” of member support and credited a holistic approach for driving increased engagement, particularly as the company adapts to a market shaped by new weight-loss medications and evolving consumer needs.
Is now the time to buy WW? Find out in our full research report (it’s free for active Edge members).
WeightWatchers (WW) Q3 2026 highlights:
- Revenue $152.9 million vs S&P analyst consensus of $152.3 million (11.2% year-on-year decline, in line)
- EPS (GAAP) $1.51 vs analyst estimates of $0.52 (significant beat)
- Adjusted EBITDA $51.66 million vs analyst estimates of $39.52 million (33.8% margin, 30.7% beat)
- Revenue guidance The company reconfirmed its revenue guidance for the full year of $627.5 million at the midpoint
- EBITDA guidance $112.5 million at the midpoint for the full year, above analyst estimates of $107.3 million
- Operating margin 23.9%, up from 4.7% in the same quarter last year
- Market capitalization $113.1 million
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from WeightWatchers’s Q3 earnings call
- Alex Fuhrman (Lucid Capital Markets) asked about the sustainability of Core+ growth and the drivers behind member migration. CEO Stephen Bye and CFO Felicia DellaFortuna explained growth was driven by both conversion from lower-tier members and new signups, with significant uptake in GLP-1 support.
- Fuhrman (Lucid Capital Markets) also questioned how the shift to higher clinical revenue would affect gross margin. DellaFortuna described efficiency gains and noted margins are holding steady as Core+ and Med+ become a larger share of the mix.
- Nathan Feather (Morgan Stanley) inquired about seasonality and clinical subscriber declines. DellaFortuna attributed Q3 declines to lapping last year’s long-term plan renewals, while COO Jon Volkmann described efforts to refine clinical intake and support members across coverage types.
- Owen Rickert (Northland Capital Markets) asked about the durability of EBITDA improvements and the early impact of new partnerships. DellaFortuna pointed to improved cost controls, while Bye said it was too early to quantify results from partnerships like Google Health and Sam’s Club.
- Justin Ages (CJS Securities) probed cash priorities and product feedback. DellaFortuna reiterated a disciplined approach to capital allocation and debt reduction, while Bye highlighted positive member feedback on the new app and the early success of the Medicare Bridge program.
Catalysts in upcoming quarters
Looking ahead, our analyst team will monitor (1) the pace of Med+ adoption, especially among seniors eligible through the Medicare Bridge Program, (2) stabilization or growth in Core+ behavioral subscribers amid ongoing product enhancements, and (3) margin trends as the mix shifts toward clinical revenue. Additional signposts will include updates on digital platform improvements and early outcomes from new distribution partnerships.
WeightWatchers currently trades at $11.42, down from $12.14 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
The best stocks for high-quality investors
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
